Science & Innovation

Update

Volume 3
Scroll
to find
out more
Two male scientists in a lab

Advancing Tobacco Harm Reduction

With the ever-changing public health and regulatory landscape, 2022 will be another important year for global Tobacco Harm Reduction (THR) strategies. To achieve real progress and meaningful change in THR, it is vital that public health policies are based on sound science, not opinion.

Find out more
scientist walking away from the camera in a lab

Explore Our Science: New R&D Virtual Visitor Experience

BAT has proudly unveiled a new virtual R&D Visitor Experience. An online tour of our global Research & Development hub in Southampton, UK, that allows people to explore our cutting-edge science and innovation.

Find out more
Dr Vel smiling at the camera

Welcoming Our New Chief Medical Officer

At BAT, we are committed to building A Better Tomorrow™ by reducing the health impact of our business. Building scientific evidence to support alternative tobacco and nicotine products is a crucial part of this mission, and we are pleased to welcome our new Chief Medical Officer, Dr Senthil Vel, MBBS MBA MFPM FFPM. Dr Senthil will play a key role in our Tobacco Harm Reduction work.

Find out more
Dr Sharon Goodall talking into a microphone

Our People:
Dr Sharon Goodall

The journey we are on is so exciting, and we are constantly evolving and adapting to meet consumer preferences.

Dr Sharon Goodall
Group Head of Regulatory Science
Find out more

Forward-Looking
Statements

This is a report by British American Tobacco p.l.c.; associate companies are excluded. References to ‘British American Tobacco’, ‘BAT’, ‘we’, ‘us’ and ‘our’ when denoting opinion refer to British American Tobacco p.l.c. (the Company, and together with its subsidiaries, the ‘Group’), and when denoting tobacco business activity refer to Group operating companies, collectively or individually as the case may be.

This report contains certain forward-looking statements, including “forward-looking” statements made within the meaning of the US Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “outlook”, “target” and similar expressions. These include statements regarding our intentions, beliefs or current expectations reflecting knowledge and information available at the time of preparation, and concerning our results of operations, financial condition, liquidity, prospects, growth, strategies and the economic and business circumstances occurring from time to time in the countries and markets in which the Company operates, including the projected future financial and operating impacts of the COVID-19 pandemic.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this report are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated.

Among the key factors that could cause actual results to differ materially from those projected in the forward looking statements are uncertainties related to the following: the impact of adverse domestic or international legislation and regulation; the inability to develop, commercialise and deliver the Group’s New Categories strategy; the impact of significant increases or structural changes in tobacco, nicotine and New Categories-related taxes; changes or differences in domestic or international economic or political conditions; the impact of serious injury, illness or death in the workplace; adverse decisions by domestic or international regulatory bodies; and the inability to lead the development and roll-out of BAT innovations (New Category products and combustibles), including as a result of unsuccessful research and development or a failure to develop robust scientific risk assessment frameworks.

The forward-looking statements reflect knowledge and information available at the date of preparation of these materials, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

The material in this report is provided for the purpose of giving information about the Company to stakeholders only and is not intended for general consumers. The Company, its directors, officers, employees, agents or advisers do not accept or assume responsibility to any other person to whom this material is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed.

The material in this Report is not provided for product advertising, promotional or marketing purposes. This material does not constitute and should not 
be construed as constituting an offer to sell, or a solicitation of an offer to buy, any of our products. Our products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.

Additional information concerning these and other factors can be found in BAT’s filings with the USSecurities and Exchange Commission (“SEC”), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC’s website, http://www.sec.gov.

1/1
Back to top of page